Patents Examined by Brittney E Donoghue
-
Patent number: 11969476Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.Type: GrantFiled: April 2, 2021Date of Patent: April 30, 2024Assignee: VISTERRA, INC.Inventors: Karthik Viswanathan, Kenneth Douglas Johnson, Obadiah Joseph Plante, James C. Delaney, Tyree J. Koch, Hamid Tissire, Andrew M. Wollacott, Boopathy Ramakrishnan
-
Patent number: 11952419Abstract: Disclosed herein are methods for treating cancer by administering to a subject having cancer antibodies against one or more of CD300c, BTN5 (Erythroid membrane-associated protein), TAPBPL (antigen processing (TAP) binding protein like protein), Skint8 (selection and upkeep of intraepithelial T cells 8 protein), and CD300f. Also disclosed herein are methods for treating autoimmune diseases by administering to a subject having an autoimmune disease an IgV domain, or a nucleic acid encoding an IgV domain, from one or more of CD300c, BTN5, TAPBPL, SkintS, and CD300f. Also disclosed herein are antibodies against CD300c and TAPBPL, and fusion proteins that can be used in the methods for treating autoimmune disease.Type: GrantFiled: July 8, 2019Date of Patent: April 9, 2024Assignee: UNIVERSITY OF CONNECTICUTInventor: Laijun Lai
-
Patent number: 11926664Abstract: Monocytopoiesis is a hematological process that supplies the periphery with monocytes and subsequently with macrophages and monocyte-derived dendritic cells. Typically, monocytes circulate in the bloodstream for a very short time before undergoing apoptosis, however, stimulatory signals can trigger monocyte survival by inhibiting the apoptotic pathway, and thus contribute to the maintenance of the inflammatory response. Accordingly, there is a need for methods and pharmaceutical compositions for modulating monocytopoiesis. Now, the inventors show that type I interferons signaling promote the differentiation of monocyte-derived phagocytes at the level of their progenitors. Importantly, IFN-alpha and -beta were found to efficiently generate the development of monocyte-derived antigen-presenting cells while having no impact on the precursor activity of conventional dendritic cells. Accordingly, modulators of type I interferon (e.g.Type: GrantFiled: July 24, 2018Date of Patent: March 12, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE LILLEInventors: Lionel Poulin, Corentin Lasseaux, Mathias Chamaillard
-
Patent number: 11918626Abstract: Provided are compositions and methods for maintaining intestinal immune homeostasis. The method comprises administering to an individual an effective amount of a VIPR2 inhibitor. The method may modulate gut resident CCR6+ ILC3 cell function.Type: GrantFiled: July 30, 2020Date of Patent: March 5, 2024Inventors: Dan R. Littman, Jhimmy Talbot
-
Patent number: 11873338Abstract: The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.Type: GrantFiled: December 20, 2019Date of Patent: January 16, 2024Assignee: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Cornelis Jacob Johannes George Bol, Pieter Fokko Van Loo, Leonardo Andres Sirulnik, Ernesto Isaac Wasserman
-
Patent number: 11845797Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.Type: GrantFiled: July 3, 2019Date of Patent: December 19, 2023Assignee: Marengo Therapeutics, Inc.Inventors: Seng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew
-
Patent number: 11840574Abstract: The present invention relates to an antibody that specifically binds to death receptor 5 (DR5) and has a function of killing cancer cells. Specifically, provided are an anti-DR5 antibody or antigen-binding fragment thereof, and a use of the antibody or antigen-binding fragment for preventing or treating cancer. The present invention is characterized in that the anti-DR5 antibody or antigen-binding fragment thereof is improved in terms of affinity to DR5, stability, and an effect of killing cancer cells.Type: GrantFiled: February 8, 2018Date of Patent: December 12, 2023Assignee: DONG-A ST CO., LTD.Inventors: Hyounmie Doh, Dongsop Lee, Hanyoung Lee, Yoojin Kim, Kyungmi Han, Eunee Jung, Donghyeon Kim, Eongsup Song, Kum-Joo Shin, Soyon Woo
-
Patent number: 11834504Abstract: The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g. acute myeloid leukaemia (AML), in a mammal, including a human.Type: GrantFiled: March 9, 2022Date of Patent: December 5, 2023Assignee: MOLECULAR PARTNERS AGInventors: Nina Reschke, Sebastian Grimm, Christian Reichen, Bernd Schlereth, Victor Levitsky, Matteo Bianchi
-
Patent number: 11834485Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.Type: GrantFiled: April 20, 2021Date of Patent: December 5, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
-
Patent number: 11827709Abstract: Provided are novel anti-?v?6 antibodies and antibody-drug conjugates and methods of using such anti-?v?6 antibodies and antibody-drug conjugates to treat cancer.Type: GrantFiled: December 4, 2020Date of Patent: November 28, 2023Assignee: Seagen Inc.Inventors: Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
-
Patent number: 11827672Abstract: Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.Type: GrantFiled: March 29, 2019Date of Patent: November 28, 2023Assignee: Eureka Therapeutics, Inc.Inventors: Jun Cui, Pengbo Zhang, Yiyang Xu, Shan Li, Yixiang Xu, Guangyan Xiong, Hongruo Yun, Lianxing Liu, Xiaomei Ge, Shaohua Xu, Hong Liu, Javier Morales
-
Patent number: 11787870Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising an LRIT2 inhibitor as an active ingredient. The LRIT2 inhibitor according to the present invention can increase the activity of immune cells, and thus can be used as an immune enhancer. Also, the LRIT2 inhibitor according to the present invention can effectively prevent or treat cancer by enhancing the immunity of an individual.Type: GrantFiled: May 15, 2019Date of Patent: October 17, 2023Assignee: GENOME AND COMPANYInventors: Kyoung Wan Yoon, Youn Kyung Houh, Bu-Nam Jeon, Jinyoung Sohn, Yun Yeon Kim, Suro Lee, Joo-Yeon Chung, Areum Jeong
-
Patent number: 11773179Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.Type: GrantFiled: January 13, 2021Date of Patent: October 3, 2023Assignee: VISTERRA, INC.Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
-
Patent number: 11680102Abstract: Anti-BAFF-R antibodies and antigen-binding fragments thereof with potentially high stability and low immunogenicity are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.Type: GrantFiled: February 19, 2021Date of Patent: June 20, 2023Assignees: Yinnuolai Biotech Ltd., City of HopeInventors: Jianbing Zhang, Hong Qin, Larry W. Kwak